Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

NCT05565794 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped slow recruitment

Conditions

Intrahepatic Cholangiocarcinoma
FGFR2 Gene Mutation
FGFR2 Gene Rearrangement
FGFR2 Gene Translocation

Interventions

DRUG: Pemigatinib

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]